Citations

Clear

4610 citation(s) found for "Lu, Brian".

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Dimopoulos, Meletios Α. , Terpos, Evangelos , Chanan-Khan, Asher, Leung, Nelson , Niesvizky, Rubén, Fermand, Jean-Paul, Bladé, Joan , Comenzo, Raymond L. , Sezer, Orhan , Palumbo, Antonio , Harousseau, Jean‐Luc, Richardson, Paul G. , Barlogie, Bart , Sonneveld, Pieter , Tosi, Patrizia , Cavo, Michèle , Rajkumar, S. Vincent , Durie, Brian G.M. , Miguel, Jesús F. San , Ludwig, Heinz , Jagannath, Sundar , Giralt, Sergio , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Rajkumar, S Vincent , Leung, Nelson , Dimopoulos, Meletios A , Terpos, Evangelos , San-Miguel, Jesus

Mayo Clinic

Journal of Clinical Oncology | October 19, 2010 | Volume: 28 | Issue: 33 | Pages: 4976-4984

10.1200/jco.2010.30.8791 | PMID 20956629 Get It

Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m2) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease.
Limited predictive ability of surrogate indices of insulin sensitivity/resistance in Asian-Indian men
Irving, Brian A. , Unni, Uma S. , Briggs, William M. , Quon, Michael J. , Muniyappa, Ranganath , Nair, K. Sreekumaran , Kurpad, Anura V.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | October 14, 2010 | Volume: 299 | Issue: 6 | Pages: E1106-E1112

10.1152/ajpendo.00454.2010 | PMID 20943755 Get It

Insulin resistance is highly prevalent in Asian Indians and contributes to worldwide public health problems, including diabetes and related disorders. Surrogate measurements of insulin sensitivity/resistance are used frequently to study Asian Indians, but these are not formally validated in this population. In this study, we compared the ability of simple surrogate indices to accurately predict insulin sensitivity as determined by the reference glucose clamp method. In this cross-sectional study of Asian-Indian men ( n = 70), we used a calibration model to assess the ability of simple surrogate indices for insulin sensitivity [quantitative insulin sensitivity check index (QUICKI), homeostasis model assessment (HOMA2-IR), fasting insulin-to-glucose ratio (FIGR), and fasting insulin (FI)] to predict an insulin sensitivity index derived from the reference glucose clamp method (SIClamp). Predictive accuracy was assessed by both root mean squared error (RMSE) of prediction as well as leave-one-out cross-validation-type RMSE of prediction (CVPE). QUICKI, FIGR, and FI, but not HOMA2-IR, had modest linear correlations with SIClamp(QUICKI: r = 0.36; FIGR: r = −0.36; FI: r = −0.27; P < 0.05). No significant differences were noted among CVPE or RMSE from any of the surrogate indices when compared with QUICKI. Surrogate measurements of insulin sensitivity/resistance such as QUICKI, FIGR, and FI are easily obtainable in large clinical studies, but these may only be useful as secondary outcome measurements in assessing insulin sensitivity/resistance in clinical studies of Asian Indians.
Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study
Ashrani, Aneel A. , Silverstein, Marc D., Rooke, Thom W. , Lahr, Brian D. , Petterson, Tanya M. , Bailey, Kent R. , Melton, L. Joseph, Heit, John A.

Mayo Clinic

Vascular Medicine | October 6, 2010 | Volume: 15 | Issue: 5 | Pages: 387-397

10.1177/1358863x10379672 | PMID 20926498 Get It

The role of venous stasis syndrome (VSS) mechanisms (i.e. venous outflow obstruction [VOO] and venous valvular incompetence [VVI]) on quality of life (QoL) and activities of daily living (ADL) is unknown. The objective of this study was to test the hypotheses that venous thromboembolism (VTE),VSS,VOO and VVI are associated with reduced QoL and ADL. This study is a follow-up of an incident VTE case-control study nested within a population-based inception cohort of residents from Olmsted County, MN, USA, between 1966 and 1990. The study comprised 232 Olmsted County residents with a first lifetime VTE and 133 residents without VTE. Methods included a questionnaire and physical examination for VSS; vascular laboratory testing for VOO and VVI; assessment of QoL by SF36 and of ADL by pertinent sections from the Older Americans Resources and Services (OARS) and Arthritis Impact Measurement Scales (AIMS2) questionnaires. Of the 365 study participants, 232 (64%), 161 (44%), 43 (12%) and 136 (37%) had VTE, VSS, VOO and VVI, respectively. Prior VTE was associated with reduced ADL and increased pain, VSS with reduced physical QoL and increased pain, and VOO with reduced physical QoL and ADL.VVI was not associated with QoL or ADL. In conclusion,VSS and VOO are associated with worse physical QoL and increased pain. VOO and VTE are associated with impaired ADL. We hypothesize that rapid clearance of venous outflow obstruction in individuals with acute VTE will improve their QoL and ADL.
Postpartum Depression Screening
Wichman, Christina L., Angstman, Kurt B. , Lynch, Brian , Whalen, Denise, Jacobson, Nathan A.

Mayo Clinic

Journal of Primary Care & Community Health | September 30, 2010 | Volume: 1 | Issue: 3 | Pages: 158-163

10.1177/2150131910380055 | PMID 23804604 Get It

Postpartum depression (PPD) has emerged as an important issue for pediatricians and family practitioners because of detrimental effects on children. PPD occurs in 10% to 22% of women who have recently given birth, but fewer than half of cases are recognized. Despite the impact of PPD, many primary care clinicians do not have systemic screening approaches implemented. This paper will review the development of a screening protocol for PPD in a multispecialty clinic, with the implementation utilizing depression care managers and the preliminary results of our process. Of the 333 screened examinations during the 4-month study, 38.1% (n = 127) were performed for the 2-month well child examination; 33.6% (n = 112) were for the 4-month examination, with 28.2% (n = 94) being performed for the 6-month well child examination. Only 15 (4.5%) were positive for possible depression with a screening compliance rate of 47.9%. No significant difference was noted in the timing of the well child visit with a positive screening test result, nor was there any difference in family medicine versus pediatric colleagues in the utilization of the screening or diagnosis of PPD. Implementation of PPD screening in a multispecialty clinic can be effective, given utilization of depression care managers.
Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma
Sekulić, Aleksandar , Kim, Su Y. , Savage, Stephanie, Einspahr, Janine G., Prasad, Anil , Sagerman, Paul, Curiel‐Lewandrowski, Clara , Bowden, G. Timothy, Warneke, James, Alberts, David S., Pittelkow, Mark R. , DiCaudo, David J. , Nickoloff, Brian J. , Trent, Jeffrey M. , Bittner, Michael , Hostetter, Galen H. , Krouse, Robert S.

Mayo Clinic

Cancer Prevention Research | September 28, 2010 | Volume: 3 | Issue: 10 | Pages: 1277-1283

10.1158/1940-6207.capr-10-0058 | PMID 20876729 Get It

Abstract Cutaneous squamous cell carcinoma (SCC) occurs commonly and can metastasize. Identification of specific molecular aberrations and mechanisms underlying the development and progression of cutaneous SCC may lead to better prognostic and therapeutic approaches and more effective chemoprevention strategies. To identify genetic changes associated with early stages of cutaneous SCC development, we analyzed a series of 40 archived skin tissues ranging from normal skin to invasive SCC. Using high-resolution array-based comparative genomic hybridization, we identified deletions of a region on chromosome 10q harboring the INPP5A gene in 24% of examined SCC tumors. Subsequent validation by immunohistochemistry on an independent sample set of 71 SCC tissues showed reduced INPP5A protein levels in 72% of primary SCC tumors. Decrease in INPP5A protein levels seems to be an early event in SCC development, as it also is observed in 9 of 26 (35%) examined actinic keratoses, the earliest stage in SCC development. Importantly, further reduction of INPP5A levels is seen in a subset of SCC patients as the tumor progresses from primary to metastatic stage. The observed frequency and pattern of loss indicate that INPP5A, a negative regulator of inositol signaling, may play a role in development and progression of cutaneous SCC tumors. Cancer Prev Res; 3(10); 1277–83. ©2010 AACR.
Japanese optic-spinal MS
Weinshenker, Brian G. , Wingerchuk, Dean M. , Weinshenker, Brian G

Mayo Clinic

Neurology | September 9, 2010 | Volume: 75 | Issue: 16 | Pages: 1404-1405

10.1212/wnl.0b013e3181f88382 | PMID 20826710 Get It

Unsupervised Classification of High-Frequency Oscillations in Human Neocortical Epilepsy and Control Patients
Blanco, Justin A. , Stead, Matt, Krieger, Abba Μ. , Viventi, Jonathan , Marsh, W. Richard , Lee, Kendall H. , Litt, Brian , Worrell, Gregory A.

Mayo Clinic

Journal of Neurophysiology | September 2, 2010 | Volume: 104 | Issue: 5 | Pages: 2900-2912

10.1152/jn.01082.2009 | PMID 20810694 Get It

High-frequency oscillations (HFOs) have been observed in animal and human intracranial recordings during both normal and aberrant brain states. It has been proposed that the relationship between subclasses of these oscillations can be used to identify epileptic brain. Studies of HFOs in epilepsy have been hampered by selection bias arising primarily out of the need to reduce the volume of data so that clinicians can manually review it. In this study, we introduce an algorithm for detecting and classifying these signals automatically and demonstrate the tractability of analyzing a data set of unprecedented size, over 31,000 channel-hours of intracranial electroencephalographic (iEEG) recordings from micro- and macroelectrodes in humans. Using an unsupervised approach that does not presuppose a specific number of clusters in the data, we show direct evidence for the existence of distinct classes of transient oscillations within the 100- to 500-Hz frequency range in a population of nine neocortical epilepsy patients and two controls. The number of classes we find, four (three plus one putative artifact class), is consistent with prior studies that identify “ripple” and “fast ripple” oscillations using human-intensive methods and, additionally, identifies a less examined class of mixed-frequency events.
Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Maurer, Matthew J. , Link, Brian K. , Ansell, Stephen M. , Micallef, Ivana N. , Kelly, Jennifer L., Macon, William R. , Nowakowski, Grzegorz S. , Inwards, David J. , Johnston, Patrick B. , Allmer, Cristine, Weiner, George J. , Cerhan, James R. , Drake, Matthew T. , Habermann, Thomas M. , Singh, Ravinder J. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Mayo Clinic

Journal of Clinical Oncology | August 17, 2010 | Volume: 28 | Issue: 27 | Pages: 4191-4198

10.1200/jco.2010.28.6674 | PMID 20713849 Get It

Purpose Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL. Patients and Methods We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were measured by liquid chromatography-tandem mass spectrometry. Results Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)2D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations. Conclusion 25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
Coordination of Substrate Binding and ATP Hydrolysis in Vps4-Mediated ESCRT-III Disassembly
Davies, Brian A., Azmi, Ishara F. , Payne, Johanna A., Shestakova, Anna , Horazdovsky, Bruce , Babst, Markus , Katzmann, David J.

Mayo Clinic

Molecular Biology of the Cell | August 12, 2010 | Volume: 21 | Issue: 19 | Pages: 3396-3408

10.1091/mbc.e10-06-0512 | PMID 20702581 Get It

ESCRT-III undergoes dynamic assembly and disassembly to facilitate membrane exvagination processes including multivesicular body (MVB) formation, enveloped virus budding, and membrane abscission during cytokinesis. The AAA-ATPase Vps4 is required for ESCRT-III disassembly, however the coordination of Vps4 ATP hydrolysis with ESCRT-III binding and disassembly is not understood. Vps4 ATP hydrolysis has been proposed to execute ESCRT-III disassembly as either a stable oligomer or an unstable oligomer whose dissociation drives ESCRT-III disassembly. An in vitro ESCRT-III disassembly assay was developed to analyze Vps4 function during this process. The studies presented here support a model in which Vps4 acts as a stable oligomer during ATP hydrolysis and ESCRT-III disassembly. Moreover, Vps4 oligomer binding to ESCRT-III induces coordination of ATP hydrolysis at the level of individual Vps4 subunits. These results suggest that Vps4 functions as a stable oligomer that acts upon individual ESCRT-III subunits to facilitate ESCRT-III disassembly.
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Turner, Jennifer , Morton, Lindsay M. , Linet, Martha S. , Vajdic, Claire M. , Monnereau, Alain, Marcos‐Gragera, Rafael , Costantini, Adele Seniori , Cerhan, James R. , Weisenburger, Dennis D. , Monnereau, Alain , Clarke, Christina A. , Kadin, Marshall E. , Maynadié, Marc , Chiu, Brian C.‐H. , Cerhan, James R , Turner, Jennifer , Vajdic, Claire M , Morton, Lindsay M , Marcos-Gragera, Rafael

Mayo Clinic

Blood | August 11, 2010 | Volume: 116 | Issue: 20 | Pages: e90-e98

10.1182/blood-2010-06-289561 | PMID 20699439 Get It

Abstract After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches for applying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications.